Patents by Inventor Julien Alistair Brown

Julien Alistair Brown has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10273247
    Abstract: A series of substituted imidazo[2,1-b]thiazole derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: April 30, 2019
    Assignee: UCB Biopharma SPRL
    Inventors: Rikki Peter Alexander, Mezher Hussein Ali, Julien Alistair Brown, Victoria Elizabeth Jackson
  • Patent number: 10087179
    Abstract: A series of fused tricyclic imidazole derivatives, in particular dihydro-1H-cyclopenta[4,5]imidazo[1,2-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: October 2, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Rikki Peter Alexander, Gareth Neil Brace, Julien Alistair Brown, Mark Daniel Calmiano, Prafulkumar Tulshibhai Chovatia, Michael Deligny, Ellen Olivia Gallimore, Jag Paul Heer, Victoria Elizabeth Jackson, Boris Kroeplien, Malcolm MacCoss, Joanna Rachel Quincey, Yogesh Anil Sabnis, Dominique Louis Léon Swinnen, Zhaoning Zhu, Uwe Heinelt, Volkmar Wehner
  • Patent number: 10004737
    Abstract: A series of substituted benzimidazole, imidazo[1,2-?]pyridine and pyrazolo[1,5-?]pyridine derivatives, and analogs thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: June 26, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Julien Alistair Brown, Mark Daniel Calmiano, Elizabeth Pearl Jones, Boris Kroeplien, James Thomas Reuberson, Matthew Duncan Selby, Michael Alan Shaw, Zhaoning Zhu
  • Patent number: 9932342
    Abstract: A series of substituted imidazo[1,2-a]pyrimidine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: April 3, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Mezher Hussein Ali, Daniel Christopher Brookings, Julien Alistair Brown, Victoria Elizabeth Jackson, Boris Kroeplien, John Robert Porter
  • Patent number: 9890174
    Abstract: A series of substituted fused tricyclic imidazole derivatives, in particular dihydro-1H-pyrano[4?,3?:4,5]imidazo[1,2-a]pyridine, 1,2,3,4-tetrahydroimidazo[1,2-a:5,4-c?]dipyridine, dihydro-1H-pyrano[3?,4?:4,5]imidazo[1,2-a]pyridine and tetrahydro-6H-cyclohepta[4,5]imidazo[1,2-a]pyridine, and analogs thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: February 13, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Rikki Peter Alexander, Julien Alistair Brown, Michael Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Sophie Jadot, Boris Kroeplien, Malcolm Mac Coss, Yogesh Anil Sabnis, Dominique Louis Léon Swinnen, Nathalie Van Houtvin, Zhaoning Zhu
  • Patent number: 9873703
    Abstract: A series of substituted imidazo[1,2-b]pyridazine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: January 23, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Mezher Hussein Ali, Daniel Christopher Brookings, Julien Alistair Brown, Martin Clive Hutchings, Victoria Elizabeth Jackson, Boris Kroeplien, John Robert Porter, Joanna Rachel Quincey
  • Patent number: 9714251
    Abstract: A series of substituted imidazo[1,2-b][1,2,4]triazine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: July 25, 2017
    Assignee: UCB Biopharma SPRL
    Inventors: Daniel Christopher Brookings, Julien Alistair Brown, Victoria Elizabeth Jackson, John Robert Porter, Joanna Rachel Quincey
  • Publication number: 20170128445
    Abstract: A series of substituted benzimidazole, imidazo[1,2-?]pyridine and pyrazolo[1,5-?]pyridine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: May 11, 2017
    Inventors: Julien Alistair Brown, Mark Daniel Calmiano, Elizabeth Pearl Jones, Boris Kroeplien, James Thomas Reuberson, Matthew Duncan Selby, Michael Alan Shaw, Zhaoning Zhu
  • Publication number: 20160376290
    Abstract: A series of substituted imidazo[2,1-b]thiazole derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: December 29, 2016
    Inventors: Rikki Peter Alexander, Mezher Hussein Ali, Julien Alistair Brown, Victoria Elizabeth Jackson
  • Publication number: 20160376276
    Abstract: A series of substituted imidazo[1,2-b][1,2,4]triazine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: December 29, 2016
    Inventors: Daniel Christopher Brookings, Julien Alistair Brown, Victoria Elizabeth Jackson, John Robert Porter, Joanna Rachel Quincey
  • Publication number: 20160376275
    Abstract: A series of substituted imidazo[1,2-b]pyridazine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: December 29, 2016
    Inventors: Mezher Hussein ALI, Daniel Christopher BROOKINGS, Julien Alistair BROWN, Martin Clive HUTCHINGS, Victoria Elizabeth JACKSON, Boris KROEPLIEN, John Robert PORTER, Joanna Rachel QUINCEY
  • Publication number: 20160376268
    Abstract: A series of fused tricyclic imidazole derivatives, in particular dihydro-1H-cyclopenta[4,5]imidazo[1,2-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: December 29, 2016
    Inventors: Rikki Peter ALEXANDER, Gareth Neil BRACE, Julien Alistair BROWN, Mark Daniel CALMIANO, Praful Tulshi CHOVATIA, Michael DELIGNY, Ellen Olivia GALLIMORE, Jag Paul HEER, Victoria Elizabeth JACKSON, Boris KROEPLIEN, Malcolm MAC COSS, Joanna Rachel QUINCEY, Yogesh Anil SABNIS, Dominique Louis Léon SWINNEN, Zhaoning ZHU, Uwe HEINELT, Volkmar WEHNER
  • Patent number: 9475820
    Abstract: A series of imidazo[1,2-a]pyrazine derivatives, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: October 25, 2016
    Assignee: UCB Biopharma SPRL
    Inventors: Jonathan Mark Bentley, Daniel Christopher Brookings, Julien Alistair Brown, Thomas Paul Cain, Laura Jane Gleave, Alexander Heifetz, Victoria Elizabeth Jackson, Craig Johnstone, Deborah Leigh, James Madden, John Robert Porter, Matthew Duncan Selby, Zhaoning Zhu
  • Publication number: 20160304530
    Abstract: A series of substituted fused tricyclic imidazole derivatives, in particular dihydro-1H-pyrano[4?,3?:4,5]imidazo[1,2-a]pyridine, 1,2,3,4-tetrahydroimidazo[1,2-a:5,4-c?]dipyridine, dihydro-1H-pyrano[3?,4?:4,5]imidazo[1,2-a]pyridine and tetrahydro-6H-cyclohepta[4,5]imidazo[1,2-a]pyridine, and analogues thereof, being potent modulators of human TNF activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: October 20, 2016
    Inventors: Rikki Peter Alexander, Julien Alistair Brown, Michael Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Sophie Jadot, Boris Kroeplien, Malcolm Mac Coss, Yogesh Anil Sabnis, Dominique Louis Léon Swinnen, Nathalie Van Houtvin, Zhaoning Zhu
  • Publication number: 20160297827
    Abstract: A series of substituted imidazo[1,2-a]pyrimidine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: October 13, 2016
    Inventors: Mezher Hussein Ali, Daniel Christopher Brookings, Julien Alistair Brown, Victoria Elizabeth Jackson, Boris Kroeplien, John Robert Porter
  • Patent number: 9309243
    Abstract: A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: April 12, 2016
    Assignee: UCB Biopharma SPRL
    Inventors: Jonathan Mark Bentley, Daniel Christopher Brookings, Julien Alistair Brown, Thomas Paul Cain, Praful Tulshi Chovatia, Anne Marie Foley, Ellen Olivia Gallimore, Laura Jane Gleave, Alexander Heifetz, Helen Tracey Horsley, Martin Clive Hutchings, Victoria Elizabeth Jackson, James Andrew Johnson, Craig Johnstone, Boris Kroeplien, Fabien Claude Lecomte, Deborah Leigh, Martin Alexander Lowe, James Madden, John Robert Porter, Joanna Rachel Quincey, Laura Claire Reed, James Thomas Reuberson, Anthony John Richardson, Sarah Emily Richardson, Matthew Duncan Selby, Michael Alan Shaw, Zhaoning Zhu
  • Publication number: 20150203486
    Abstract: A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: July 5, 2013
    Publication date: July 23, 2015
    Inventors: Jonathan Mark Bentley, Daniel Christopher Brookings, Julien Alistair Brown, Thomas Paul Cain, Praful Tulshi Chovatia, Anne Marie Foley, Ellen Olivia Gallimore, Laura Jane Gleave, Alexander Heifetz, Helen Tracey Horsley, Martin Clive Hutchings, Victoria Elizabeth Jackson, James Andrew Johnson, Craig Johnstone, Boris Kroeplien, Fabien Claude Lecomte, Deborah Leigh, Martin Alexander Lowe, James Madden, John Robert Porter, Joanna Rachel Quincey, Laura Claire Reed, James Thomas Reuberson, Anthony John Richardson, Sarah Emily Richardson, Matthew Duncan Selby, Michael Alan Shaw, Zhaoning Zhu
  • Publication number: 20150191482
    Abstract: A series of imidazo[1,2-?]pyrazine derivatives, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorder; and oncological disorders.
    Type: Application
    Filed: July 5, 2013
    Publication date: July 9, 2015
    Inventors: Jonathan Mark Bentley, Daniel Christopher Brookings, Julien Alistair Brown, Thomas Paul Cain, Laura Jane Gleave, Alexander Heifetz, Victoria Elizabeth Jackson, Craig Johnstone, Deborah Leigh, James Madden, John Robert Porter, Matthew Duncan Selby, Zhaoning Zhu
  • Patent number: 9029392
    Abstract: Disclosed are a series of quinoline and quinoxaline derivatives comprising a fluorinated ethyl side-chain, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: May 12, 2015
    Assignee: UCB Pharma S.A.
    Inventors: Andrew Harry Parton, Mezher Hussein Ali, Daniel Christopher Brookings, Julien Alistair Brown, Daniel James Ford, Richard Jeremy Franklin, Judi Charlotte Neuss, Joanna Rachel Quincey, Jackalyn Hinkins
  • Publication number: 20130296338
    Abstract: A series of quinoline and quinoxaline derivatives comprising a fluorinated ethyl side-chain, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Application
    Filed: September 2, 2011
    Publication date: November 7, 2013
    Applicant: UCB PHARMA S.A.
    Inventors: Andrew Harry Parton, Mezher Hussein Ali, Daniel Christopher Brookings, Julien Alistair Brown, Daniel James Ford, Richard Jeremy Franklin, Barry John Langham, Judi Charlotte Neuss, Joanna Rachel Quincey